Treatment of renal carcinoma using antibodies against the EGFr

Details for Australian Patent Application No. 2003239505 (hide)

Event Publications

11 September 2003 Complete Application Filed

Priority application(s): 60/382,152 20.05.02 US

5 February 2004 Application Open to Public Inspection

Published as AU-A-2003239505

2 August 2007 Change of Name(s) of Applicant(s), Section 104

Immunex Corporation; Abgenix, Inc. The name of the applicant has been changed to Immunex Corporation; Amegen Fremont Inc. 2004

30 August 2007 Corrigenda

Change of Names(s) of Applicant(s), Section 104 - 2003 Under the name Amegen Fremont Inc. and Immunex Corporation, application No. 2003239505, under INID(71), correct the name to read Amgen Fremont Inc. and Immunex Corporation

17 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.